Patient characteristics before and after matching with weighted variable
| Characteristics . | Transplant cohort . | Before matching . | P value∗ . | After matching . | P value† . |
|---|---|---|---|---|---|
| Nontransplant cohort . | Nontransplant cohort . | ||||
| n = 239 . | n = 243 . | n = 105 . | |||
| Patient sex, Female | 33.1% | 32.9% | 1 | 34.3% | 1 |
| Age, y | 55.5 (9.49) | 60.9 (10.6) | <.001 | 57.9 (9.36) | .052 |
| Hemoglobin (g/dL) | 9.58 (1.88) | 10.8 (2.22) | <.001 | 9.63 (1.74) | .816 |
| Platelet (×109/L) | 188 (270) | 270 (291) | <.001 | 168.9 (237.3) | .510 |
| White blood cells (×109/L) | 13.1 (17.3) | 12.9 (13.7) | .863 | 11.7 (13.22) | .942 |
| Circulating blasts ≥1% | 54% | 43.2% | .023 | 66% | .099 |
| Constitutional symptoms | 55.2% | 28.8% | <.001 | 54.4% | 1 |
| DIPSS | |||||
| Low | 7.53% | 17.6% | .001 | 7.9% | 1 |
| Int-1 | 30.1% | 37.1% | 29.3% | ||
| Int-2 | 47.7% | 37.6% | 46.9% | ||
| High | 14.6% | 7.7% | 15.9% | ||
| Driver mutations | |||||
| Calreticuline | 17.6% | 29.8% | <.001 | 31.4% | .005 |
| JAK2 V617F | 53.6% | 56.3% | 57.7% | ||
| MPL | 6.3% | 6.5% | 4.2% | ||
| Triple negative | 22.6% | 7.3% | 6.7% | ||
| HMR | 42.3% | 50.6% | .08 | 64.0% | .006 |
| MIPSS70 | |||||
| Low | 6.3% | 34.7% | <.001 | 19.7% | .003 |
| Intermediate | 60.3% | 46.1% | 43.5% | ||
| High | 33.5% | 19.2% | 36.8% | ||
| Mutations | |||||
| ASXL1 | 31.4% | 42.4% | .016 | 51.9% | .003 |
| EZH2 | 4.2% | 6.1% | .436 | 7.9% | .292 |
| IDH1 | 1.7% | 1.6% | 1 | 4.1% | .254 |
| IDH2 | 3.4% | 4.1% | .838 | 13.4% | .249 |
| SRSF2 | 11.5% | 11.4% | 1 | 15.9 % | .548 |
| U2AF1 | 6.7% | 12.2% | .050 | 15.5% | .021 |
| TP53 | 10.9% | 4.9% | .024 | 5.9% | .306 |
| DNMT3A | 5.9% | 8.6% | .316 | 1.7% | .362 |
| TET2 | 15.5% | 29.4% | <.001 | 25.9% | .058 |
| Characteristics . | Transplant cohort . | Before matching . | P value∗ . | After matching . | P value† . |
|---|---|---|---|---|---|
| Nontransplant cohort . | Nontransplant cohort . | ||||
| n = 239 . | n = 243 . | n = 105 . | |||
| Patient sex, Female | 33.1% | 32.9% | 1 | 34.3% | 1 |
| Age, y | 55.5 (9.49) | 60.9 (10.6) | <.001 | 57.9 (9.36) | .052 |
| Hemoglobin (g/dL) | 9.58 (1.88) | 10.8 (2.22) | <.001 | 9.63 (1.74) | .816 |
| Platelet (×109/L) | 188 (270) | 270 (291) | <.001 | 168.9 (237.3) | .510 |
| White blood cells (×109/L) | 13.1 (17.3) | 12.9 (13.7) | .863 | 11.7 (13.22) | .942 |
| Circulating blasts ≥1% | 54% | 43.2% | .023 | 66% | .099 |
| Constitutional symptoms | 55.2% | 28.8% | <.001 | 54.4% | 1 |
| DIPSS | |||||
| Low | 7.53% | 17.6% | .001 | 7.9% | 1 |
| Int-1 | 30.1% | 37.1% | 29.3% | ||
| Int-2 | 47.7% | 37.6% | 46.9% | ||
| High | 14.6% | 7.7% | 15.9% | ||
| Driver mutations | |||||
| Calreticuline | 17.6% | 29.8% | <.001 | 31.4% | .005 |
| JAK2 V617F | 53.6% | 56.3% | 57.7% | ||
| MPL | 6.3% | 6.5% | 4.2% | ||
| Triple negative | 22.6% | 7.3% | 6.7% | ||
| HMR | 42.3% | 50.6% | .08 | 64.0% | .006 |
| MIPSS70 | |||||
| Low | 6.3% | 34.7% | <.001 | 19.7% | .003 |
| Intermediate | 60.3% | 46.1% | 43.5% | ||
| High | 33.5% | 19.2% | 36.8% | ||
| Mutations | |||||
| ASXL1 | 31.4% | 42.4% | .016 | 51.9% | .003 |
| EZH2 | 4.2% | 6.1% | .436 | 7.9% | .292 |
| IDH1 | 1.7% | 1.6% | 1 | 4.1% | .254 |
| IDH2 | 3.4% | 4.1% | .838 | 13.4% | .249 |
| SRSF2 | 11.5% | 11.4% | 1 | 15.9 % | .548 |
| U2AF1 | 6.7% | 12.2% | .050 | 15.5% | .021 |
| TP53 | 10.9% | 4.9% | .024 | 5.9% | .306 |
| DNMT3A | 5.9% | 8.6% | .316 | 1.7% | .362 |
| TET2 | 15.5% | 29.4% | <.001 | 25.9% | .058 |